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ABSTRACT: The Diels-Alder reaction, a [4+2] 
cycloaddition of a conjugated diene to a dienophile, is 
one of the most powerful reactions in synthetic 
chemistry. Biocatalysts capable of unlocking new and 
efficient Diels-Alder reactions would have major 
impact. Here we present a molecular-level description of 
the reaction mechanism of the spirotetronate cyclase 
AbyU, an enzyme shown here to be a bona fide natural 
Diels-Alderase. Using enzyme assays, X-ray crystal 
structures and simulations of the reaction in the enzyme, 
we reveal how linear substrate chains are contorted 
within the AbyU active site to facilitate a transannular 
pericyclic reaction. This study provides compelling 
evidence for the existence of a natural enzyme evolved 
to catalyze a Diels-Alder reaction, and shows how 
catalysis is achieved.  
The Diels-Alder reaction is a [4+2] cycloaddition that 
involves the reorganization of a six-electron system to 
form a cyclohexene.1 This transformation is of major 
synthetic value for the preparation of substituted six-
membered rings with the creation of up to four new 
stereocenters.2–5 Development of protein catalysts for 
these reactions is a major goal in biocatalysis, and would 
potentially enable new, efficient and ‘green’ synthetic 
routes to a wide variety of valuable bioactive 
compounds. Whilst a small number of natural enzymes 
have been shown to be capable of catalyzing [4+2] 
cycloaddition reactions6–13 the molecular details of how 
these transformations are achieved, and whether they do 
indeed proceed via a formal Diels-Alder route, remain 
unknown.14–16 Detailed mechanistic studies of protein-
catalyzed Diels-Alder reactions have to date been 
restricted to de novo designed enzymes and catalytic 
antibodies.17,18 These valuable test subjects, however, 
exhibit poor catalytic efficiencies, limiting their value as 
biocatalysts.19,20 Establishing whether natural enzymes 
have evolved Diels-Alderase activity, and in particular, 
how such catalysis is achieved at the molecular level, is 
crucial for the development of efficient protein Diels-
Alder catalysts.15-18,21  
We focus on the putative natural Diels-Alderase AbyU, 
from the abyssomicin C biosynthetic pathway. The 
spirotetronate antibiotic abyssomicin C (1), first isolated 
from the marine actinomycete Verrucosispora maris 
AB-18-032, is a potent inhibitor of bacterial folate 
metabolism effective against Mycobacterium 
tuberculosis and multi-drug resistant clinical isolates of 
Staphylococcus aureus.22 The biosynthesis of this 
compound proceeds via the formation of a 
heterobicyclic ring system, comprising a tetronic acid 
ring (4-hydroxy-[5H]furan-2-one) spiro-linked to 
cyclohexene23 (Figure 1). Formation of this carbocycle 
is postulated to occur via an enzyme-catalyzed 
intramolecular [4+2] cycloaddition between the 
exocyclic methylene group and conjugated diene of 
4.24,25 This transformation could conceivably progress 
via a formal Diels-Alder reaction. Studies of enzymes 
from other spirotetronate biosynthetic pathways have 
demonstrated the presence of a stand-alone cyclase that 
facilitates [4+2] cycloaddition.12,13 However, the 
molecular basis of how this reaction is performed and 
whether it does indeed progress via a concerted 
mechanism are unknown. Given that spirotetronate 
cyclases share no amino acid sequence identity to other 
putative natural Diels-Alderases,4,6–13 it is likely that 
these enzymes represent a distinct protein scaffold in 
which a Diels-Alder reaction may take place.  
An N-terminally hexa-histidine tagged variant of AbyU 
was recombinantly over-expressed in E. coli B834(DE3) 
cells and purified to homogeneity. Purified recombinant 
AbyU was found to be a homogeneous, dimeric species 
in solution, of >95% purity (Figure S1).  
  
Figure 1. Proposed abyssomicin C biosynthetic pathway, 
synthetic substrate analogues (6 and 7) and biosynthesized 
spirotetronates (8 and 9). During the biosynthesis of 
abyssomicin C the heptaketide product 2 of the AbyB1-3 
polyketide synthase is condensed with glycerate, presented 
on the free-standing acyl carrier protein AbyA3, to form a 
5-membered ring in 3. Acetylation of 3 followed by 
elimination, catalyzed by the AbyA4/AbyA5 enzyme 
couple, introduces the exocyclic methylene of 4. 
Intramolecular [4+2] cycloaddition of 4 is catalyzed by 
AbyU and yields the spirotetronate abyssomicin C 
precursor 5. Structural and functional studies of AbyU 
reported herein were conducted using substrate analogues 6 
and 7, which were enzymatically converted to 8 and 9 
respectively. 
Substrate 6, an analogue of the proposed AbyU substrate 
4 (Figure 1) was synthesized and incubated with AbyU 
for 30 mins at 25 °C. Analysis of the resulting reaction 
mixture by HPLC indicated that a single product had 
been formed with the same retention time as a standard 
of 8, prepared by heating diketone 6 for 2 days in 
chloroform (Figure 2). The mass of this product (m/z = 
367.53) and 1H-NMR of the crude material were in 
accord with the spirocyclic product 8 (Figure S2 and SI).  
There was no evidence of cyclization occurring in 
control reactions lacking enzyme, or containing heat-
denatured AbyU (Figure 2). Steady-state kinetic 
characterization of the AbyU catalyzed conversion of 6 
to 8 gave kcat = 564 ± 43 min-1, Km = 102 ± 17 µM and 
kcat/Km = 5.5 ± 0.2 min-1µM-1. This compares with a rate 
for the non-AbyU catalyzed reaction of k = 0.014 min-1, 
consistent with a > 4 x 104 fold enhancement in rate in 
the presence of enzyme (Figure S3). Whilst these data 
give compelling support for an AbyU mediated [4+2] 
cycloaddition, diketone 6 is known to slowly undergo a 
Diels-Alder reaction at room temperature (40% 
conversion after one week in chloroform26 and Figure 
S3).  To further explore the potential value of AbyU, a 
substrate less prone to undergo cyclization was 
investigated.  
Since in general, electron-deficient dienophiles are 
favored in Diels-Alder reactions, a mixture of epimeric 
alcohols 7, the synthetic precursor of diketone 6, was 
selected. Neither incubation of 7 in aqueous buffer for 
24 hrs, nor heating of 7 in chloroform for 2 days gave 
the cycloadduct 9. In contrast, incubation of 7 with 
AbyU for 30 mins at 25 °C yielded two products (Figure 
2) with the correct mass (m/z=369.63) for the epimeric 
cycloaddition products 9 (Figure S2), indicating that an 
intramolecular [4+2] cycloaddition had taken place. No 
synthetic standard of 9 was available for comparison. To 
circumvent this, the mixture of 9 from the AbyU-
catalyzed reaction was purified by preparative TLC and 
oxidized using Dess-Martin periodinane, to yield a less 
polar product (Figure 2 and SI), which exhibited a 
retention profile, mass spectrum (m/z=367.53), and 1H 
NMR data in accord with the synthetic spirotetronate 8. 
No product was detected in control reactions with heat-
denatured AbyU. Together, these data show that AbyU 
is capable of catalyzing [4+2] cycloaddition reactions, 
including one that cannot be readily achieved under 
standard conditions of prolonged heating. 
 
Figure 2. HPLC analysis demonstrating AbyU catalyzed 
[4+2] cycloaddition.  Traces are shown for assay mixes 
comprising: (a), synthetic standard of diketone 6; (b), 6 
incubated with 280 µM AbyU; (c), 6 incubated with 280 
µM heat denatured AbyU; (d), synthetic standard of Diels-
Alder product 8; (e), synthetic standard of diol 7 (as a 
mixture of epimeric alcohols); (f), 7 incubated with 280 
µM AbyU; (g), 7 incubated with 280 µM heat denatured 
AbyU; (h), synthetic standard of Diels-Alder product 8; (i), 
product from the purification of 9 isolated from (f) 
followed by oxidation using Dess-Martin periodinane to 
give 8. Standard incubation conditions comprised 10 mM 
substrate with or without AbyU for 30 mins at 25 oC.  
Figure 2. 
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 To analyze the molecular basis of the AbyU-catalyzed 
cycloaddition, we determined the crystal structure of the 
enzyme (Figure 3).  
 
Figure 3. Crystal structure of AbyU and substrate binding 
mode. (a), Overall fold of the AbyU dimer. Individual 
monomers are colored blue and green respectively. (b), 
Cut-away view through crystal structure of AbyU, 
revealing the size and location of the enzyme active site. 
The protein is shown in space filling representation and is 
colored by electrostatic surface potential. The residues 
Glu19 and Arg122 are shown in stick format and colored 
by atom. (c), Detailed view of the AbyU active site 
highlighting key residues and bound molecule of HEPES. 
Coloring is by atom. (d), Superposition of the 
computationally predicted binding modes of 4, 5 and the 
atropisomer of 5 within the active site of AbyU.  
For the purposes of phase determination, a mutant of 
AbyU (AbyU_DM) was generated in which the residues 
Leu73 and Leu139 were replaced with 
selenomethionines, using methionine encoding codons 
(Figure S4). AbyU_DM was recombinantly over-
expressed in E. coli and purified to homogeneity. As 
with AbyU, AbyU_DM was found to be dimeric in 
solution (Figure S1). The crystal structure of AbyU_DM 
was determined to 1.7 Å resolution using the single 
wavelength anomalous dispersion (SAD) method as 
applied to selenomethionine (SeMet) labeled crystals of 
AbyU_DM. This structure was subsequently used as a 
molecular replacement search model to elucidate the 
crystal structure of AbyU. The Cα RMSD between 
AbyU_DM and AbyU is 0.4 Å (Figure S5). Both 
unlabeled and SeMet labeled AbyU_DM catalyzed the 
conversion of 6 to 8 (Figure S6), confirming their 
catalytic competency.  
AbyU is a homodimer comprised of two eight stranded 
anti-parallel β-barrels with (+1)8 topology (Figure 3). 
The central channel of each barrel is sealed at one end 
by a salt bridge formed by the side-chains of Glu19 and 
Arg122 and is capped at the other by a largely 
hydrophobic loop formed by the β1-β2 linker (residues 
Asp26-Gly36; Figure 3). Molecular dynamics 
simulations demonstrate the flexible nature of the 
capping loop and its ability to gate active site access 
(Figure S7). The central channel of the barrel forms an 
extended largely hydrophobic cavity of ~720 Å3 that 
constitutes the active site of the enzyme, formed by the 
side chains of the residues Val21, Phe41, Phe60, Tyr76, 
Phe95, Tyr106, Trp124 and Met126 (Figure 3). Electron 
density corresponding to a single bound HEPES 
molecule is observed in the active sites of each of the 8 
copies of AbyU and three of the four copies of 
AbyU_DM that comprise their respective asymmetric 
units (Figures 3 and S5).  
AbyU’s closest structural homolog is the allene oxide 
cyclase PpAOC2:27 a more elaborated eight stranded 
barrel with a significantly different active site 
architecture (Figure S8). Comparison of the sequence of 
AbyU with those of other known spirotetronate cyclases 
reveals minimal sequence conservation (Figure S9), 
raising the intriguing possibility that mutation of the 
internal cavity of barrel-like structures may offer a route 
to generating enzymes capable of performing [4+2] 
cycloaddition reactions using a range of substrates. 
To establish the catalytic mechanism of AbyU, we first 
investigated the binding mode of the substrate associated 
with the reaction. Docking of 4, 5 and the atropisomer of 
5 in the active site supports a binding mode where the 
substrate dienophile is positioned next to Phe41 and the 
diene close to Trp124 (Figures 3 and S10). In this 
binding mode, a hydrogen bond is formed between 
Tyr76 and the lactone carbonyl, which may contribute to 
substrate specificity. Binding is largely hydrophobic, 
with good steric complementarity between the enzyme 
and substrate. In the docked conformation of 4, the C13-
C14 and C10-C15 distances (bonds formed in the 
product) are 3.6 and 3.9 Å, respectively. This indicates 
that the enzyme active site accommodates the substrate 
in a potentially reactive Michaelis conformation. 
Molecular dynamics (MD) simulations of the enzyme 
with product 5 bound show that the binding mode 
obtained from docking is stable. Little structural change 
of the enzyme is required to accommodate the substrate; 
comparison of MD simulations of the apo and substrate-
bound enzymes primarily show changes in the loop 
covering the active site cavity (residues 26-36), which 
becomes more ordered on substrate binding (Figure S7).  
Quantum mechanics/molecular mechanics (QM/MM) 
molecular dynamics simulations, which incorporate the 
effects of the enzyme on the reaction28, reveal that the 
reaction in the enzyme proceeds via a concerted, 
asynchronous Diels-Alder mechanism (Figures S10 and 
S11). They show that the substrate can react from the 
binding mode described above. The structural and 
 electronic properties of the transition state (Figures S10 
and S11) indicate that AbyU is indeed a true Diels-
Alderase. Free-energy profiles of the reaction were 
calculated at the SCC-DFTB/ff14SB QM/MM level, 
with the reaction simulated in the reverse direction, 5 to 
4. The active site is well organized to catalyze the 
reaction and the interactions noted above are maintained 
throughout. In the transition state, C13-C14 bond 
formation is more advanced than C10-C15 bond 
formation, which occurs predominantly on the downhill 
path to the product (Figure S10). Higher-level density 
functional theory calculations (M06-2X/6-31G(d,p)) 
confirm the identification of the transition state structure 
and the order of bond formation (Figure S11). Both 
levels of theory thus show that the [4+2] cycloaddition 
of 4 to 5 occurs via an asynchronous concerted Diels-
Alder mechanism. The transition state structures 
calculated for the reaction of the isolated substrate are 
similar to those in the enzyme, which indicates that the 
primary catalytic function of the enzyme is to provide a 
preorganized active site that binds a reactive 
conformation of the substrate, from which the reaction 
can occur with a relatively low free energy barrier.  
In summary, we report the structural and functional 
characterization of the spirotetronate cyclase AbyU, 
establishing the molecular basis of the [4+2] 
cycloaddition reaction catalyzed by this enzyme. AbyU 
is a co-factor independent, stand-alone Diels-Alderase 
with a low-molecular weight beta-barrel scaffold. The 
simplicity of this enzyme makes it a compelling and 
practical target for engineering. It has further been 
shown capable of accepting and acting upon non-natural 
substrates, including those that do not readily cyclize 
upon heating. This study presents unequivocal evidence 
of the existence of a natural enzyme capable of 
catalyzing a formal Diels-Alder reaction and paves the 
way for the exploitation of AbyU as a biocatalyst for 
industrial applications and the designed synthesis of 
novel bioactive compounds. 
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Materials and Methods 
1. Gene cloning 
The gene encoding AbyU was amplified from Verrucosispora maris AB-18-032 genomic DNA 
by polymerase chain reaction (PCR) using the primers 5’-
AAGTTCTGTTTCAGGGCCCGATGACTGAGCGACTGGAGACG-3’ and 5’- 
ATGGTCTAGAAAGCTTTATCACGGATCCTGCTCGGCGAG-3’, introducing appropriate 
overlap sequences (underlined) for insertion into the plasmid pOPINF,1 pre-cut with KpnI 
and HindIII. Ligations were carried out using the In-Fusion cloning kit (Clonetech) following 
the manufacturer’s protocol. The resulting construct, abyU::pOPIN encodes an N-terminally 
hexa-histidine tagged variant of AbyU. The gene encoding the Leu73Met/Leu139Met AbyU 
double mutant (AbyU_DM) was amplified by PCR from a commercially sourced (MWG 
EurofinsTM) plasmid containing a synthetic abyU_DM gene (fig. S3) using the primers 5’-
AAGTTCTGTTTCAGGGCCCGATGACGGAACGCCTTGAAACC-3’ (forward) and 5’-
ATGGTCTAGAAAGCTTTATCATTCACCCATCAGAATGCG-3’ (reverse), introducing 
appropriate overlap sequences (underlined) for insertion into the plasmid pOPINF, pre-cut 
with KpnI and HindIII. Ligations were carried out using the In-Fusion cloning kit (Clonetech) 
following the manufacturer’s protocol. The resulting construct, abyU_DM::pOPINF encodes 
an N-terminally hexa-histidine tagged variant of AbyU_DM. Leucine residues targeted for 
mutation to methionine residues in AbyU_DM, were selected based upon comparative 
sequence analysis of AbyU with known homologues of this protein. Methionine residues 
occupy positions equivalent to Leu73 and Leu139 in at least one other AbyU homologue. The 
sequences of all constructs were verified by DNA sequencing, following which each was 




2. Protein expression  
The recombinant over-expression of AbyU and AbyU_DM was achieved using the same 
general procedure. Cultures of E. coli B834(DE3) cells harboring either abyU::pOPINF or, 
abyU_DM::pOPINF, were grown in 1 L Luria-Bertani (LB) medium, supplemented with 100 
μg/mL carbenicillin, at 37 °C with shaking, until the optical density of the cultures at 600 nm 
had reached 0.6. Protein expression was induced by the addition of IPTG to a final 
concentration of 0.5 mM. Cultures were grown for an additional 16 hrs with shaking at 20 °C, 
following which cells were harvested by centrifugation, supernatant liquids removed, and the 
remaining cell pellets stored at −80 °C. 
The recombinant over-expression of selenomethionine (SeMet) labeled AbyU_DM was 
achieved as follows. A culture of E. coli B834(DE3) cells harboring abyU_DM::pOPINF was 
grown in 10 mL of LB media, supplemented with 100 μg/mL carbenicillin,  at 37 °C with 
shaking for 16 hrs. The cell culture was centrifuged, the supernatant liquid removed, and the 
remaining cell pellet resuspended in 1 mL of double-distilled water. This cell suspension was 
used to inoculate 1 L of M9 medium (preheated to 37 °C), supplemented with 
SelenoMethionine Medium Nutrient Mix (Molecular Dimensions), 50 mg of 
selenomethionine and 100 μg/mL carbenicillin. The culture was grown 37 °C with shaking, 
until the optical density at 600 nm had reached 0.6. At this point an additional 100 mg of 
selenomethionine was added and the cell suspension grown for an additional 30 minutes at 37 
°C with shaking. The culture was induced by the addition of IPTG to a final concentration of 
0.5 mM, following which it was grown for a further 16 hrs at 37 °C with shaking. Cells were 
harvested by centrifugation, the supernatant liquid removed, and the remaining cell pellet 




3. Protein purification  
All recombinant proteins were purified using the same general strategy. Frozen cell pellets 
were thawed on ice and resuspended in 30 mL of His-Load buffer (20 mM Tris-HCl, 150 mM 
NaCl, 20 mM imidazole, pH 7.5) supplemented with an EDTA free protease inhibitor cocktail 
tablet (Roche). Cell suspensions were sonicated, and resulting cell lysates clarified by 
centrifugation, following which supernatant liquids were removed and applied to a 5 mL 
HisTrap column (GE life sciences) pre-charged with nickel. Each column was washed with 10 
column volumes of His-Load buffer in order to remove any non-specifically bound proteins. 
Bound protein was eluted over 50 mL using a linear gradient of 0-50% His-Load to His-Elute 
buffer (20 mM Tris-HCl, 150 mM NaCl, 500 mM imidazole, pH 7.5), with fractionation (2 
mL) throughout. For the purification of SeMet labeled AbyU_DM, His-Load and Elute 
buffers were supplemented with 2 mM TCEP. Fractions found to contain the target protein of 
interest, as established by monitoring the absorbance of the column eluent at 280 nm followed 
by SDS-PAGE analysis, were pooled and concentrated to 2 mL. For unlabeled recombinant 
AbyU and AbyU_DM, concentrated protein samples were applied to a 16/60 Superdex 75 
column (GE life sciences), pre-equilibrated in 20 mM Tris-HCl, 150 mM NaCl, pH 7.5. For 
SeMet labeled recombinant AbyU_DM, concentrated protein samples were applied to a 16/60 
Superdex 75 column (GE life sciences), pre-equilibrated in 20 mM Tris-HCl, 150 mM NaCl, 2 
mM TCEP, pH 7.5. Fractions found to contain the target protein of interest, as determined by 
monitoring the absorbance of the column eluent at 280 nm followed by SDS-PAGE analysis, 
were pooled, concentrated to ~10 mg/mL, and flash frozen in liquid nitrogen for storage at 
−80 °C prior to use. SDS-PAGE and size exclusion chromatography analysis of all three 
recombinant proteins revealed that they were dimeric, homogeneous species in solution, of 
>95% purity (fig. S1). 
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4. AbyU enzyme activity assays 
The ability of AbyU to accept the compounds 6 or 7 as substrates for [4+2] cycloaddition was 
assessed in 20 μL assay mixes comprising 280 μM AbyU, 10 mM 6 or 7, 20 mM Tris-HCl, 150 
mM NaCl, 10% methanol, pH 7.5. Assays were initiated by the addition of cold enzyme (4 °C) 
and incubated for 15 mins at 25 °C, following which they were quenched by the addition of 30 
μL of ice-cold acetonitrile and centrifuged at 18000 rpm to remove precipitated protein. 
Control experiments were performed using the assay mixes and reaction conditions described 
above, but either excluding enzyme, or using heat denatured enzyme. For assays 
incorporating heat denatured enzyme a 100 μL 1 mg/ml solution of AbyU was heated at 100 
°C for 10 minutes, following which appropriately sized aliquots of protein solution were 
removed and added to the assay mix. Assays to assess the ability of unlabeled and SeMet 
labeled AbyU_DM to catalyze [4+2] cycloaddition of 6 were performed using an identical 
approach to that outlined above.  
Assay components were extracted in 2  1 mL of ethyl acetate and dried under a stream of 
nitrogen gas. Resulting residues were re-suspended in 100 μL of acetonitrile, of which 50 μL 
was subjected to LC-MS analysis. Chromatographic separations were performed using a 
Phenomenex LUNA column (5 μ, C18, 100 Å, 4.6  250 mm), using a linear gradient of 10-
90% acetonitrile/0.5% formic acid. Mass spectrometry was performed using a Waters ZQ 
Micromass spectrometer. 
 
5. Elucidation of AbyU catalyzed and non-AbyU catalyzed reaction rates 
Reaction rates for the conversion of 6 to 8 in the presence or absence of AbyU were 
determined spectrophotometrically by monitoring the rate of disappearance of 6 at 300 nm 
(ε300 nm = 18400 M-1cm-1). All assays were performed in reaction buffer comprising 20 mM 
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Tris-HCl, 150 mM NaCl, pH 7.5, at 20 oC, using a 1 mm path length quartz cuvette, with a 1 
mM stock solution of 6 dissolved in acetonitrile. For the calculation of the non-enzymatically 
catalysed conversion of 6 to 8, 45 μM 6 was incubated in reaction buffer for 100 minutes and 
the change in absorbance monitored throughout. The resulting data were fitted to a single 
exponential of the form: 
                                                               ! = !! !!!" 
Where [A] is substrate concentration at time t, [A0] is substrate concentration at time 0, and k 
is the reaction rate. 
To calculate the rate of the AbyU catalyzed conversion of 6 to 8, 6 (0-200 μM) was incubated 
in reaction buffer with AbyU, at a final concentration of 1 nM. Initial rates were calculated by 
monitoring the change in absorbance for at least 1 minute, following which rates for the non-
enzymatically catalysed conversion of 6 to 8 at each substrate concentration were subtracted. 
Background subtracted initial rates were plotted as a function of substrate concentration and 
fitted to a rectangular hyperbola of the form:  
!! = !!"#[!][!]!! + [!]  
Where v0 is initial velocity, [E] is enzyme concentration, [A] is substrate concentration at time 
0, kcat is the enzyme catalyzed reaction rate and Km is the Michaelis constant.  
All reactions were repeated in triplicate. Data fitting was performed using GraphPad Prism. 
 
6. Protein Crystallization  
Conditions supporting the growth of crystals of unlabeled AbyU and SeMet labeled 
AbyU_DM were initially identified using the sitting drop vapor diffusion method at 18 °C, 
employing commercially available crystallization screens (Molecular Dimension Limited), 
mixing 0.2 μL of protein solution with 0.2 μL of reservoir solution. Diffraction quality crystals 
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of both proteins were grown using the hanging drop vapor diffusion method, employing 
reservoir solutions comprising 0.02 M magnesium chloride, 0.1 M HEPES pH 7.5, 18% w/v 
poly(acrylic acid) sodium salt MW 5100. Crystals took 3-5 days to grown to optimum size.  
 
7. Diffraction data collection and structure determination 
Crystals selected for diffraction data collection were mounted in appropriately sized 
litholoops (Molecular Dimensions Ltd), submerged in reservoir solution supplemented with 
20% glycerol, and flash-cooled in liquid nitrogen prior to analysis. Diffraction data were 
collected at Diamond light source, UK, on beamlines I04-1 and I24. Diffraction data were 
processed with iMosflm,2 and scaled and merged using Aimless 3, as implemented within the 
CCP4 suite of programs.4 5% of the data were set aside for the calculation of Rfree. 
Identification of heavy atom sites and the resulting initial phase calculation was carried out 
using SHELX5 employing data collected from crystals of SeMet labeled AbyU_DM. An initial 
model was built using the Autobuild pipeline in Phenix6 and further extended using 
ARP/wARP7 as implemented in the CCP4 suite of programs.4 Iterative rounds of manual 
model building and refinement were carried out using COOT8 and REFMAC.9 The final 
AbyU_DM model comprises residues 10-140 of the native sequence, 99 water molecules, and 
3 molecules of HEPES.  
The structure of AbyU was determined by molecular replacement in PHASER,10 using the 
AbyU_DM structure as a search model. The initial AbyU model was built using ARP/wARP,7 
followed by further iterative rounds of rebuilding and refinement with COOT8 and REFMAC . 
9 The final AbyU model comprises residues 6-141 of the native sequence, 76 water molecules, 
5 molecules of glycerol, and 8 molecules of HEPES. Data collection, phasing and refinement 
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statistics for AbyU_DM and AbyU are provided in table S1. Protein structure figures have 
been prepared using PYMOL.11 
 
8. Docking studies  
Molecular docking of the natural substrate 4 and the bicyclic products 5 (the abyssomycin C 
precursor and its atropisomer) of AbyU was performed using the crystal structure complexed 
with HEPES. Chain A was used and the bound HEPES removed; selenomethionine was 
replaced with methionine. The substrate and product structures were initially built with 
GaussView and then optimized at the B97D/6-31+G(d,p) level. The substrate was optimized 
with C11-C12 in the cis conformation. AutoDockTools 1.5.4 was used to add Gasteiger 
charges, merge the non-polar hydrogens and define rotatable bonds for docking. In the 
substrate, the C11-C12 and C2-C3 bonds were defined as non-rotatable (to maintain the cis 
conformation and enforce positioning of the tetronate ring in line with the correct 
stereoisomer of the product, respectively) and all other formally single bonds were defined as 
rotatable. Subsequently, docking was performed with AutoDock Vina 1.1.2,12 using a grid of 
151815 Å centered on the active site cavity, with side-chains of residues Tyr95, Phe113, 
Trp143 and Met145 (that line the cavity) defined with rotatable single bonds. The 
exhaustiveness was set to 25. 
 
9. Molecular dynamics simulations 
Explicit solvent molecular dynamics simulations were performed of the apo-enzyme and the 
complex with the bicyclic product 5 (the precursor of abyssomycin C). In all cases, chain A of 
the crystal structure of SeMet labeled AbyU_DM (complexed with HEPES) was used for the 
initial coordinates, with HEPES removed and selenomethionine replaced with methionine. 
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For the complexed structures (AbyU_DM with the bicyclic product), coordinates of the pose 
consistent with the 1st docking pose of the linear substrate were used, together with the side-
chain positions of Tyr76, Phe95, Trp124 and Met126 obtained from docking. Hydrogens were 
added with the AmberTools program reduce; Asp43 was treated as protonated (predicted pKa 
values by PropKa 3.113,14 were 9.7 and 11.1 for the apo and complexed structures, respectively) 
and His88 as doubly protonated (consistent with the hydrogen bonding network and a 
predicted pKa value of 8.2). Missing heavy atoms were added using the AmberTools program 
tleap. Initial addition of water (at least 5 Å around the protein) was performed using the 
solvate program (http://www.mpibpc.mpg.de/grubmueller/solvate); 5 waters in the cavity in 
the apo simulations were kept and any waters in the cavity in the complexed structure were 
deleted. Subsequently, tleap was used to add additional waters to form a rectangular box (75
8169 Å) and 3 sodium ions to neutralize the net charge. 
MD simulations were performed with the Amber14 programs sander (for minimization) and 
pmemd.cuda (for MD on GPUs, using the default SPFP model)15 and using the AMBER 
ff14SB force field for the protein,16 the TIP3P water model and GAFF17 for the products 
(parameters assigned with Antechamber). Particle-mesh Ewald summation was used in 
conjunction with periodic boundary conditions and a cut-off for direct-space non-bonded 
interactions of 8 Å. Partial charges of the products consistent with ff14SB were calculated 
using the PyRED server.18 Prior to production simulation at 298 K and 1 atm, the following 
procedure was carried out: 1) optimize solvent and hydrogen positions (minimization for 300 
steps followed by 50 ps langevin dynamics simulation in the NVT ensemble); 2) 300 steps of 
minimization and quick heating to 298 K (20 ps in NVT ensemble with 2 fs timestep, using 
langevin dynamics with SHAKE and initial random velocities assigned at 25K) with harmonic 
positional restraints on Cα atoms only (force constant: 5 kcal mol−1Å−2); 3) release of 
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positional restraints in 4 steps of 10 ps MD in the NPT ensemble (langevin dynamics with 
PME, SHAKE and timestep of 2 fs, a collision frequency of 1 and the Berendsen barostat with 
a pressure relaxation time of 1 ps); 4) 1 ns equilibration of temperature and pressure in the 
NPT ensemble (conditions as in previous step). Production simulation was then performed in 
the NVT ensemble using weak temperature control (MD with SHAKE and a 2 fs timestep, 
using the Berendsen thermostat with the time constant for coupling to the heat bath of 10 ps).  
Clustering analysis was performed with the AmberTools program cpptraj on the 
conformations sampled from 100 to 500 ns in the 4 apo simulations, based on the root-mean-
square deviation of the heavy atoms in the 26-36 loop after alignment on the Cα atoms of the 
β-barrel. The Hierarchical Agglomerative approach was used with default settings and 
requesting 6 clusters. Root-mean-square fluctuations of Cα atoms were also calculated after 
alignment on the Cα atoms of the β-barrel. 
 
10. QM/MM simulations 
Approximate QM/MM umbrella sampling simulations at the SCC-DFTB/ff14SB level were 
performed starting from the 4 different poses of the AbyU product 5 obtained from docking 
(abyssomycin C, lacking the ether-bridge). Prior to QM/MM simulation, hydrogen atoms and 
a 20 Å sphere of water (TIP3P model) were added, centered on the spiro carbon of the 
product, and an initial MM structure optimization was performed. Thereafter, the product 
and the side chain of Trp124 were treated with the semi-empirical SCC-DFTB method19 (a 
link atom was placed between Cα and Cβ in the Trp side chain), and the rest of the protein 
and water were treated with the ff14SB16 and TIP3P force-fields, respectively. Atoms further 
than 20 Å from the central spiro carbon were held fixed to their starting positions. All 
QM/MM simulations were run using the Amber14 program sander, a 1 fs integration 
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timestep, a 10 Å cut-off for non-bonded interactions and in the NVT ensemble with 
temperature controlled with the Berendsen thermostat. After a short heating phase (10 ps 
with velocities assigned at 50 K, heating to 300 K with a 1 ps coupling constant to the heat 
bath), unbiased QM/MM MD simulations were run for each pose (at 300 K with a 4 ps 
coupling constant to the heat bath). Snapshots between 20 and 100 ps of QM/MM MD were 
used to start umbrella sampling. The reaction coordinate used to follow the Diels-Alder 
reaction was the distance between the center-of-mass of the dienophile carbons (C14, C15) 
and the center-of-mass of the diene carbons to which they bond (C13, C10). By using this 
reaction coordinate definition, no bias is applied as to which carbon-carbon bond is formed 
or broken first (or indeed whether or not the bonds are formed/broken synchronously). 
Umbrella sampling was performed using 26 windows from reaction coordinate values 1.3 Å 
to 3.8 Å (in steps of 0.1 Å). A restraint of 100 kcal mol−1Å−1 and 2 ps of simulation was used 
for each umbrella sampling window. Reaction coordinate values were recorded every 1 fs, and 
used for input to the Weighted Histogram Analysis Method (WHAM)9 resulting in the 
potential of mean force (free energy) along the reaction coordinate. For each docking pose, at 
least 8 different snapshots from the unbiased QM/MM MD simulation were used to start 
QM/MM umbrella sampling along the reaction. Only for docking poses ranked 1 and 3, 
multiple consistent PMFs with a substrate minimum were obtained; for docking pose 2 no 
PMFs with a substrate minimum were obtained; for docking pose 4 only one reasonable PMF 
with a substrate minimum was obtained (and the SCC-DFTB SCF could not be converged in 






11. Gas phase DFT calculations              
Transition states for the formation of the AbyU products 5 (the precursor of abyssomycin C 
and its atropisomer) in the gas phase were optimized at the M06-2X/6-31G(d,p) level,20–22 
using the QST3 method23 in Gaussian09.24 This functional, for which dispersion interactions 
were included in its parameterization, is suitable for modeling Diels-Alder reactions.25 
Transition states were confirmed using frequency calculations (indicating 1 imaginary 
frequency). Initial guesses for the ‘reactant’, transition state and ‘product’ geometries used as 
input for the QST3 calculations were obtained from relaxed scans at the B97D/6-31G(d,p) 
level, starting from the products. In order to generate a reasonable minimum energy path 
(without discontinuities; see Fig. S10B), scanning was performed first by increasing the C10-
C15 distance up to ~2.4 Å, followed by scanning along the C13-C14 distance up to 2.6 Å 
whilst keeping C10-C15 fixed between 2.40-3.05 Å and finally scanning further along C13-
C14 (up to 3.6 Å). All scans were performed in steps of 0.05 Å. 
 
12. Electrostatic potential calculations 
For figures that show an electrostatic potential projected on the molecular surface of protein 
X-ray crystal structures, the Poisson-Boltzmann electrostatic potential on the solvent 
accessible surface is shown, with potential values ranging from −15 kT/e (red) to 15 kT/e 
(blue). This was calculated with the APBS-plugin26 in PyMOL, using a PQR file with AMBER 






13. Chemical synthesis  13.1 General experimental details  All reagents were sourced from commercial suppliers and were used without further purification unless stated otherwise. Where anhydrous conditions were necessary, standard Schlenk syringe-septa techniques were used with flame dried glassware under a positive pressure of nitrogen. Anhydrous THF, Et2O, hexane and CH2Cl2 were dried by passing through a modified Grubbs system of alumina columns, manufactured by Anhydrous Engineering and stored over 3Å molecular sieves. All stated temperatures below ambient are the temperatures of the cooling baths, unless otherwise stated. Flash column chromatography was performed according to the procedures used by Still et al. using silica gel 60 (Fisher Scientific or Aldrich) and a suitable eluent. TLC was performed with aluminum backed silica TLC plates (Merck-Keiselgel 60 F254) with a suitable solvent system and was visualized using UV fluorescence (254 & 366 nm) and/or developed with potassium permanganate. Infra-red spectra were recorded on a Perkin Elmer Spectrum 100 FTIR with an ATR accessory and frequencies are reported in wavenumbers (cm-1). 1H and 13C NMR spectra were recorded using Jeol ECP 400 MHz, Jeol ECS 400 MHz, Varian 400MR (400 MHz) and Varian VMR S500 MHz spectrometers 




13.2 Organic synthesis of substrates and standards    
 Reagents and condition: a) DHP (1.5 eq.), PPTS (0.15 eq.), CH2Cl2, rt, 16 h; b) DIBAL-H (1.05 eq.), CH2Cl2, 90 °C, 2 h; c) i-Pr2NH (1.2 eq.), n-BuLi (1.2 eq.), ethyl propionate (1.2 eq.), THF, 15 to 78 °C, 1 h; d) ()-CSA (1.2 eq.), C6H6, reflux, 14 h; e) H2 (1 atm), Pd/C (10%), Et2O, rt, 2 h; f) (MeO)2P(O)CH3 (1.1 eq.), n-BuLi (1.1 eq.), THF, 78 °C, then n-BuLi (1.1 eq.), TESCl (2.0 eq.), 14 h; g) trans,trans-2,4-hexadienal (1.2 eq.), Ba(OH)2 (1.2 eq.), THF, H2O, rt, 2 h; h) THF:AcOH:H2O (12:3:2), rt, 2 h; i) BAIB (1.2 eq.), TEMPO (0.2 eq), CH2Cl2, rt, 2 h; j) dimethyl formamide dimethyl acetal, 110 °C, 8 h; k) 2 M HCl in Et2O, NaBH3CN (1.01 eq.), MeOH, rt, 2 h; l) CH3I (4 eq.), MeOH, 16 h, rt, then NaHCO3(aq), CHCl3, rt, 2 h; m) i-Pr2NH (1.2 eq.), n-BuLi (1.2 eq.), THF, 0 °C to 78 °C, 6 min; n) Dess-Martin periodinane (1.1 eq.), CH2Cl2, rt, 1 h; o) CHCl3, hydroquinone, 70 °C, 2 days.  The synthetic approach to lactone SI-5 was based upon that of Andrus et al.27 Roche ester SI-1 was THP protected followed by DIBAL-H reduction to aldehyde SI-3 which underwent aldol addition with ethyl propionate to give aldol adduct SI-4. Treating aldol adduct with ()-CSA in refluxing benzene deprotected the THP group and subsequent cyclization gave unsaturated lactone SI-5. Catalytic hydrogenation of SI-5 gave the required syn lactone SI-6 as the major diastereomer. Reaction of lactone SI-6 with lithiated phosphonate ester gave SI-7 which underwent a Horner-Wadsworth-Emmons olefination to give triene SI-8. TES deprotection and oxidation gave aldehyde SI-10 (63% over 9 steps) which was coupled with the known tetronate SI-14 (prepared in 3 steps and 
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69% overall yield from commercially available SI-11 as previously described28,29) to give a mixture of epimeric alcohols 7. Dess-Martin periodinane oxidation of 7 gave keto tetronate 6 (42% over 2 steps). Heating 6 in CHCl3 in the presence of hydroquinone at 70 
oC for 2 days30 gave the Diels-Alder product, 8 which was used as a standard in the analysis of products from incubation studies with the enzyme AbyU.   
(5R)-3,5-Dimethyl-5,6-dihydro-2H-pyran-2-one SI-5 
 
A mixture of isomers of known27 hydroxy esters SI-4 (4.33 g, 15.79 mmol) and ()-CSA (4.65 g, 18.95 mmol) in benzene (160 mL) was refluxed for 16 h. The water generated was trapped by means of a Dean-Stark apparatus. The reaction mixture was allowed to cool to room temperature before the benzene was removed under reduced pressure and the residue was redissolved in CH2Cl2 (100 mL). The organic phase was washed with half saturated brine (200 mL) to remove the acid, dried over MgSO4, concentrated then purified by vacuum distillation to give lactone SI-5 (1.91 g, 96%) as a colorless liquid. 1H NMR (400 MHz, CDCl3): δH 6.48 (1H, dd, J 3.0, 1.5, 4-H), 4.34 (1H, ddd, J 11.0, 5.0, 1.0, 6-HH), 3.99 (1H, dd, J 11.0, 8.5, 6-HH), 2.64 (1H, m, 5-H), 1.90 (3H, t, J 2.0, 3-CH3), 1.09 (3H, d, J 8.5, 5-CH3). 13C NMR (100 MHz, CDCl3): δC 165.5 (C-2), 145.8 (C-4), 127.4 (C-3), 72.4 (C-6), 29.3 (C-5), 17.3 (3-CH3) and 15.8 (5-CH3). FTIR (neat) 1711 cm-1. [α]D20.7 = 32.6 (c 0.12, CDCl3), lit.27 value = 34.7 (c 0.1, CDCl3). 





A mixture of lactone SI-5 (2.62 g, 20.75 mmol) and Pd (10%)/Charcoal (2.21 g) was stirred in Et2O (250 mL) at 10 °C (cryostat in i-PrOH) for 16 h under an atmosphere of H2 (balloon). The reaction was monitored by TLC and was stopped when the spot no longer exhibited UV activity. The mixture was filtered through a plug of silica and filter paper to remove the Pd/C catalyst, the resulting solution was concentrated to give a near colorless oil (2.68 g, 99%). 1H NMR showed the cis/trans ratio to be 3:1. 1H NMR (400 MHz, CDCl3): δH (Major) 4.26 (1H, ddd, J 11.0, 4.5, 2.0, 6-HH), 3.76 (1H, dd, J 11.0, 9.0, 6-HH), 2.48 (1H, m, 3-H), 2.04 (2H, m, 4-H2), 1.20 (3H, d, J 7.0, 3-CH3), 1.15 (1H, m, 5-H), 0.93 (3H, d, J 6.5, 5-CH3). 13C NMR (100 MHz, CDCl3): δC 174.6 (C-2), 74.9 (C-6), 36.8, 35.3, 28.6, 17.4 (CH3) and 16.9 (CH3). 







Dimethyl (3S,5R)-3,5-dimethyl-2-oxo-6-(triethylsilyloxy)hexylphosphonate SI-7 
 
To a solution of dimethyl methylphosphonate (1.17 ml, 10.82 mmol) in anhydrous THF (100 mL) at 78 °C was added n-BuLi (1.44 M, 7.51 mL, 10.82 mmol) and the reaction was stirred for 30 minutes under an atmosphere of nitrogen. A solution of lactone SI-6 (1.26 g, 9.84 mmol) in anhydrous THF (5 mL) was added via syringe and the reaction was stirred for 1 h. n-BuLi (1.44 M, 7.51 mL, 10.82 mmol) was added dropwise and the reaction was stirred for 1 h. Et3SiCl (3.3 mL, 19.68 mmol) was introduced and the reaction was slowly warmed to 25 °C overnight. The reaction was quenched with saturated NH4Cl/H2O/MeOH (3:6:1) and extracted with Et2O (3 × 40 mL). The combined Et2O extracts were washed with brine (50 mL), dried over MgSO4, and concentrated to give crude SI-7. Flash chromatography on silica gel (2:1 to 1:2 n-hexane/Et2O) gave SI-7 (3.35 g, 93%) as a 3:1 mixture of diastereomers: 1H NMR (400 MHz, CDCl3): δH (Major) 3.76 (6H, d, J 11.0, 2 × OCH3), 3.46-3.37 (2H, m, 6-H2), 3.18-3.03 (2H, m, 1-H2), 2.88-2.79 (1H, m, 3-H), 1.79 (1H, ddd, J 13.5, 7.5, 6.0), 1.63-1.53 (1H, m), 1.09 (3H, d, J 7.0, CH3), 1.05-0.99 (1H, m), 0.93 (9H, t, J 8.0, Si(CH2CH3)3), 0.88 (3H, d, J 7.0, CH3) and 0.56 (6H, q, J 8.0, Si(CH2CH3)3). 13C NMR (100 MHz, CDCl3): δC 205.8 (d, J 7, C-2), 67.8 (C-6), 52.0 (d, J 6.5, 2 × OCH3), 52.08 (d, J C,P  6.5), 45.3 (d, J 2, C-3), 40.0 (d, J 131.0, C-1), 36.6, 33.6, 17.3, 16.9, 6.9 (3 × CH3), 4.5 (3 × CH2). 






Phosphonate ester SI-7 (1.01 g, 2.76 mmol) was dissolved in THF (reagent grade, 14.4 mL) and barium hydroxide (0.708 g, 4.13 mmol) was added. trans,trans-2,4-Hexadienal (0.364 ml, 3.31 mmol) in THF (47.5 mL) was added slowly to the stirring solution followed by water (9.5 mL) added dropwise and then stirred for 3 h. Brine (40 mL) was added, the layers separated and the aqueous layer extracted with EtOAc (3 × 40 mL), dried over MgSO4 and concentrated in vacuo. The crude product was purified by flash chromatography eluting with 5-10% EtOAc in petroleum ether 40-60 °C to give silyl ether SI-8 (0.742 g, 80%) as a near colorless oil in a 3:1 ratio of diastereomers:  1H NMR (400 MHz, CDCl3): δH (Major) 7.23 (1H, dd, J 15.0, 11.0, 7-H), 6.57 (1H, dd, J 15.0, 11.0, 9-H), 6.26-6.13 (3H, m, 6-H, 8-H, 10-H), 6.00-5.95 (1H, dq, J 11.0, 7.0, 11-H), 3.44 (1H, distorted dd, J  9.5, 5.5), 3.38-3.33 (1H, m), 2.86 (1H, ddq, J 7.0), 1.83 (3H, d, J 7.0), 1.63-1.59 (1H, m), 1.16-1.07 (1H, m), 1.10 (3H, d, J 7.0), 0.94 (9H, t, J 8.0), 0.89 (3H, d, J  7.0), 0.58 (6H, q, J 8.0). 13C NMR (100 MHz, CDCl3): δC 204.7 (C-5), 142.9 (C-7), 142.1 (C-9), 135.4 (C-11), 131.5 (C-10), 128.3 (C-8), 127.3 (C-6), 68.1 (C-1), 42.4 (C-4), 37.5 (C-3), 33.9 (C-2), 18.7 (C-12), 17.7 and 17.4 (2-CH3 and 4-CH3), 6.8 and 4.6 (Si(CH2CH3)3).  







To a stirring solution of protected silyl ether SI-8 (0.297 g, 0.87 mmol) in THF (12 mL) was added AcOH (3 mL) and H2O (2 mL). The resulting yellow solution was stirred for 1 h and monitored by TLC. Upon full consumption of the starting material, the reaction was quenched by the slow addition of saturated NaHCO3(aq) until the evolution of CO2 gas ceased. The aqueous layer was extracted with EtOAc (3 × 20 mL), combined organics were washed with brine (30 mL), dried over MgSO4 and concentrated to give crude yellow oil which was purified by silica gel column chromatography eluting with 20% EtOAc in petroleum ether 40-60 °C to give alcohol SI-9 as a yellow oil (0.193 g, 98%) in a 3:1 ratio of diastereomers: 1H NMR (400 MHz, CDCl3): δH 7.26 (1H, dd, J 15.0, 11.0, 7-H), 6.58 (1H, dd, J  15.0, 10.5, 9-H), 6.26-6.14 (3H, m, 6-H, 8-H and 10-H), 5.96 (1H, m, 11-H), 3.48-3.38 (2H, m, 1-H2), 2.84 (1H, m, 4-H), 1.96-1.86 (1H, m), 1.83 (3H, d, J  7.0, 12-H3), 1.63 (1H, br. s., OH), 1.60-1.52 (1H, m), 1.22-1.14 (1H, m, 3-HH), 1.11 (3H, d, J 7.0, 4-CH3), 0.93 (3H, d, J 7.0, 2-CH3). 13C NMR (100 MHz, CDCl3): δC 204.3 (C-5), 143.3 (C-7), 142.5 (C-9), 135.7 (C-11), 131.5 (C-10), 128.2 (C-8), 127.1 (C-6), 68.2 (C-1), 42.7 (C-4), 36.7 (C-3), 34.3 (C-2), 18.8 (CH3), 18.5 (CH3) and 17.4 (CH3). 








To a stirring solution of alcohol SI-9 (0.187 g, 0.82 mmol) in anhydrous CH2Cl2 (5 mL) under an atmosphere of nitrogen was added (diacetoxyiodo)benzene (BAIB, 0.319 g, 0.99 mmol) and TEMPO (0.026 g, 0.17 mmol) and stirred at 23 °C for 3 h. TLC confirmed complete conversion of starting material, the reaction was quenched by the addition of saturated Na2S2O3(aq) (5 mL) and NaHCO3(aq) (1 mL) then stirred for a further 30 minutes. The layers were separated and the aqueous later was extracted with CH2Cl2 (3 × 15 mL). The combined organics were washed with brine (30 mL), dried over MgSO4 and concentrated to give an orange oil. Silica gel chromatography was carried out eluting with 10-20% EtOAc in petroleum ether 40-60 °C to give aldehyde SI-10 as a yellow oil (0.177 g, 96%) as a 3:1 ratio of diastereomers.  1H NMR (400 MHz, CDCl3): δH  9.60 (1H, d, J  2.0, CHO), 7.27 (1H, m, 7-H), 6.59 (1H, ddd, J 14.5, 10.5, 4.0, 9-H), 6.27-6.09 (3H, m, 6-H, 8-H and 10-H), 5.97 (1H, dq, J 14.5, 7.0, 11-H), 2.85 (1H, sextet, J 7.0, 4-H), 2.36 (1H, m, 2-H), 2.19 (1H, dt, J 14.5, 7.5, 3-HH), 1.83 (3H, d, J 7.0, 12-H3), 1.35-1.24 (1H, m, 3-HH), 1.12 (3H, d,  J  7.0, 4-CH3), 1.09 (3H, d, J  7.0, 2-CH3). 13C NMR (100 MHz, CDCl3): δC  204.6 (C-1), 203.0 (C-5), 143.7 (C-7), 142.7 (C-9), 135.9 (C-11), 131.5 (C-10), 128.1 (C-8), 127.0 (C-6), 44.4 (C-2), 41.8 (C-4), 33.7 (C-3), 18.8 (C-12), 17.7 (CH3) and 13.9 (CH3). 






n-BuLi (1.41 M, 0.494 mL, 0.696 mmol) was added dropwise to a stirred solution of i-Pr2NH (0.098 mL, 0.696 mmol) in anhydrous THF (5.4 mL) under an atmosphere of nitrogen at 0 °C for 30 minutes. The LDA solution was cooled to 100 °C, a solution of lactone SI-14 (0.073 g, 0.58 mmol) in anhydrous THF (2.7 mL) was added via cannula, and the solution was stirred for 6 minutes at 100 °C as a pale yellow solution. A solution of aldehyde SI-10 (0.128 g, 0.58 mmol) in anhydrous THF (3.4 mL) was added slowly via cannula. The resulting solution was stirred at 100 °C for 1 h to form an orange solution, quenched with saturated NH4Cl(aq) (20 mL), and slowly warmed to 25 °C. The layers were separated, and the aqueous layer was extracted with EtOAc (3 × 40 mL). The combined organic layers were washed with brine (40 mL), dried over MgSO4, and concentrated. Flash chromatography eluting with 10-20% EtOAc in petroleum ether 40-60 °C gave 7 as a near colorless oil (0.138 g 68 %) as a mixture of epimers which was used directly in the next step.   
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Dess-Martin periodinane (15% wt., 0.45 mL, 0.159 mmol) was added to a solution of tetronate 7 (0.050 g, 0.145 mmol) in CH2Cl2 (6 mL) and stirred at room temperature for 1 h. TLC confirmed complete conversion of starting material to a less polar product. The reaction was quenched by the addition of saturated Na2S2O3(aq) (10 mL) and NaHCO3(aq) (2 mL) stirred for a further 30 minutes. The layers were separated and the aqueous later was extracted with CH2Cl2 (3 x 20 mL). The combined organics were washed with brine (15 mL), dried over MgSO4 and concentrated. Standard silica gel chromatography was carried out eluting with 10-20% EtOAc in petroleum ether 40-60 °C to give 6 as a pale yellow oil (0.031 g, 62%) as a 4:1 mixture of diastereomers. 1H NMR (500 MHz, CDCl3): 
δH (Major)  7.24 (1H, dd, J 15.0, 11.0, 7-H), 6.59 (1H, dd, J 15.0, 11.0, 9-H), 6.29-6.08 (3H, m, 6-H, 8-H and 10-H), 5.96 (1H, m, 11-H), 5.25 (1H, d, J 3.0, 6’-HH), 5.20 (1H, d, J  3.0, 6’-HH), 4.10 (3H, s, OCH3), 3.64 (1H, m, 2-H), 2.80 (1H, m, 4-H), 2.22 (1H, m, 3-HH), 1.82 (3H, d, J 7.0, 12-H3), 1.32 (1H, m, 3-HH), 1.14 (3H, d, J 6.5, 2-CH3) and 1.12 (3H, d, J 6.5, 4-CH3). 13C NMR (125 MHz, CDCl3): δC 203.2 (C-5), 200.5 (C-1), 168.5 (C-5’), 166.2 (C-2’), 148.8 (C-4’), 143.2 (C-7), 142.1 (C-9), 135.3 (C-11), 131.4 (C-10), 128.2 (C-8), 127.2 (C-6), 104.6 (C-1’), 95.7 (C-6’), 62.7 (OCH3), 42.2 (C-2), 42.0 (C-4), 35.6 (C-3), 18.6 (C-12), 17.8 (2-CH3), 16.9 (4-CH3). 







Diels-Alder adduct 8 
 
Tetronate 6 (57 mg, 0.167 mmol) and hydroquinone (1 mg) was dissolved in CHCl3 (5 mL) and heated in a sealed tube at 75 °C for 2 days. The reaction mixture was cooled to room temperature and concentrated to give 44 mg of crude compound. A portion of the crude was purified (20 mg) by silica gel chromatography (10-20% EtOAc in petroleum ether 40-60 °C) to give Diels-Alder adduct 8 (29 mg, 51%) as a 4:1 mixture of diastereomers. 1H NMR (500 MHz, CDCl3): δH (Major) 6.46 (1H, dd, J 16.5, 7.0, 9-H), 6.24 (1H, d, J 16.5, 8-H), 5.85 (1H, app. dt, J 10.0, 3.0, 12-H), 5.67 (1H, app. dt, J 10.0, 3.0, 11-H), 3.90 (3H, s, OMe), 3.44 (1H, m, 10-H), 3.11 (1H, m, 4-H), 2.94 (1H, sextet, J 6.5, 6-H), 2.63 (1H, m, 13-H), 2.39 (1H, dd, J 14.5, 8.0, 14-HH), 1.86 (1H, ddd, J 15.0, 6.0, 4.0, 5-HH), 1.81 (1H, dd, J 14.5, 4.5, 14-HH), 1.18 (1H, overlapping m, 5-HH), 1.20 (3H, d, J 7.0, 19-H3), 1.18 (3H, d, J 6.5, 18-H3), 1.14 (3H, d, J 7.5, 17-H3). 13C NMR (125 MHz, CDCl3): δC 204.3 (C-7), 200.6 (C-3), 178.2 (C-16), 169.9 (C-1), 141.5 (C-9), 136.7 (C-12), 131.6 (C-8), 121.8 (C-11), 106.9 (C-2), 86.0 (C-15), 61.7 (OCH3), 46.63 (C-4), 46.57 (C-6), 44.6 (C-10), 38.9 (C-5), 36.6 (C-14), 29.3 (C-13), 21.1 (C-17), 17.0 (C-19) and 16.6 (C-18).  




Diels-Alder adduct 8 from incubation of alcohols 7 with AbyU followed by purification then oxidation 
 
Alcohol 9 (0.8 mg, 2.513 µmol) obtained from purification by prep-TLC (100% CH2Cl2) of the product from incubation of alcohols 7 with AbyU was dissolved in anhydrous CH2Cl2 (0.103 mL) and was cooled to 0 °C under an atmosphere of nitrogen. Dess-Martin periodinane (15% wt., 8 µL) was added, and then the reaction was stirred at room temperature for 1 h. Saturated NaHCO3(aq) (2 mL) was added and the aqueous phase was extracted with Et2O (3 × 5 mL). The combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. The crude product was purified by prep-TLC (50-100% CH2Cl2 in petroleum ether 40-60 °C) giving ketone 8 (0.2 mg, 25%) as a colorless oil. The 1H-NMR spectrum correlates with synthetic 8 and the literature.30 
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Dimethyl (3S,5R)-3,5-dimethyl-2-oxo-6-(triethylsilyloxy)hexylphosphonate SI-7 
 














(2R,4S,6E,8E,10E)-2,4-Dimethyl-1-hydroxy-dodeca-6,8,10-trien-5-one  SI-9 
 























Comparison on 1H NMR of synthetic Diels-Alder adduct 8 (top) with Diels-Alder adduct 8 from incubation of alcohols 7 with AbyU followed by purification then oxidation (bottom) 
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Fig. S1. Size exclusion chromatography and SDS-PAGE analysis of purified recombinant 
AbyU, AbyU_DM and SeMet labeled AbyU_DM. A, Chromatogram showing the elution 
profiles of AbyU, AbyU_DM and SeMet labeled AbyU_DM from a Superdex 75 10/300 
column (GE Healthcare) pre-equilibrated in 20 mM Tris-HCl, 150 mM NaCl, pH 7.5. 0.2 mg 
of each protein was loaded onto the column. Eluted peaks were observed by monitoring the 
absorbance of the column eluent at 280 nm. Inset, SDS-PAGE analysis of AbyU, AbyU_DM 
and SeMet labeled AbyU_DM. B, Comparative analysis of the elution volumes of AbyU, 
AbyU_DM and SeMet labeled AbyU_DM with those of Bio-Rad protein standards 
(thyroglobulin, 670 kDa; γ-globulin, 158 kDa; ovalbumin, 44 kDa; myoglobin, 17 kDa; 
vitamin B12 1.35 kDa). Protein standards were analyzed using the same column and buffer 
conditions as those used for AbyU proteins. The theoretically calculated molecular mass of an 


























                                               
 
Fig. S2. Mass spectra of AbyU catalyzed reaction products. Positive ion mode ESI MS of 8 
and both C3 epimers of product 9 recovered from AbyU catalyzed [4+2] cycloaddition 
reactions (see fig. 2). Product masses are consistent with the proposed structures of both 8 
with m/z of [M + Na]+ = 367.53 (theoretically predicted: 367.15), and 9 [M + Na]+ = 369.63 





Fig. S3. Kinetic characterization of the non-enzymatically catalyzed and AbyU catalyzed 
conversion of 6 to 8. A, spontaneous conversion of 6 to 8 monitored spectrophotometrically. 
Data are fitted to a single exponential as detailed in SI methods. B, plot of initial velocity/[E] 
vs. substrate concentration for the AbyU catalyzed conversion of 6 to 8. Data are fitted to a 
rectangular hyperbola as detailed in SI methods. Values for initial rates are mean values 
calculated from three repeats of each experiment. Error bars are standard errors from the 
mean. 	






























kcat = 564 	43 min-1 
Km = 102 	17 μM  
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ATG ACG GAA CGC CTT GAA ACC CGT CCT CAA GCG CTG CTC ATC AAA GTA CCG 
ACT GAG ATC GTG GTG AAA GTC GTG GAT GAC GTG GAT GTC GCT GCA CCA GCC 
GTT GGT CAG GTT GGG AAG TTT GAC GAT GAA CTG TAC GAC GAA GCT GGT GCG 
CAG ATT GGC ACC TCT TCC GGC AAT TTC CGC ATT GAG TAC GTA CGT CCG ACT 
GAT GGA GGC TTG ATG ACC TAC TAT CAG GAG GAT ATC ACC CTG TCG GAT GGC 
GTG ATT CAT GCG GAA GGT TGG GCC GAT TTC AAC GAC GTT CGT ACG AGC AAA 
TGG GTG TTT TAT CCG GCA ACA GGC GTT TCA GGA CGC TAT CTG GGC TTA ACC 
GGG TTT CGC CAA TGG CGT ATG ACG GGT GTC CGG AAA AGT GCC GAA GCG CGC 
ATT CTG ATG GGT GAA 
 
Fig. S4. Sequence of the synthetic abyU_DM gene used in this study. Codons encoding 
methionine residues in abyU_DM that replace those encoding leucine residues in abyU are 
highlighted in yellow. Codon optimization was performed by the commercial supplier MWG 






Fig. S5. Structural comparison of AbyU with SeMet labeled AbyU_DM. A, Superposition of 
the crystal structures of AbyU (blue) and AbyU_DM (green) highlighting the location of the 
residues 73 and 139. The calculated RMSD between the two structures is 0.4 Å. B, 2Fobs-Fcalc 
simulated annealing omit maps (gray mesh) contoured at 1.0 σ of HEPES molecules identified 
in the active sites of each of the 8 copies of AbyU that comprise the asymmetric unit of the 
AbyU protein crystal, and 3 of the 4 copies of AbyU_DM that comprise the asymmetric unit 
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Fig. S6. HPLC analysis demonstrating the ability of unlabeled and SeMet labeled 
AbyU_DM to catalyze [4+2] cycloaddition. HPLC analysis of reaction mixtures comprising: 
A, 10 mM 6; B, 6 incubated for 30 minutes at 25 °C with 280 μM unlabeled AbyU_DM; C, 6 
incubated for 30 minutes at 25 °C with 280 μM denatured unlabeled AbyU_DM; D, 8 
generated using a synthetic Diels-Alder reaction; E, 10 mM 6; F, 6 incubated for 30 minutes at 
25 °C with 280 μM SeMet labeled AbyU_DM; G, 6 incubated for 30 minutes at 25 °C with 280 























Fig. S7. Flexibility and active site access in AbyU. A, Representative conformations from 
molecular dynamics (MD) simulations of the loop covering the active site cavity (residues 26-
36), obtained by clustering analysis (see SI methods). In gray: the crystal structure (with 
HEPES removed); in green: a snapshot from simulation of the apo form representing 80% of 
the conformations sampled from 100-500 ns in 4 independent simulations; in light orange 
and blue: residues 26-36 of snapshots representing 10% and 8% of the conformations 
sampled, respectively. The main residues forming hydrophobic contacts that can hold the 
loop closed (V28, V30, P31, L72 and F95) are shown as sticks for the closed starting 
conformation (gray) and the main open conformation (green). B, Entrance to the active site 
cavity in the closed starting conformation (gray) and the main open conformation (green). C, 
Difference in loop structure and movement in the apo and complexed simulations. Cα root-
mean square deviations (RMSD) in two representative MD simulations of the apo form (top) 
and the product 5 bound form (precursor of abyssomycin C; starting complex obtained from 
docking, see section S4). Blue line depicts the RMSD of the residues making up the strands of 
the β-barrel, red line depicts the RMSD of the loop residues (26-36) after alignment on the 
barrel strands. D, Flexibility measured by root-mean-square fluctuation (from 50-500 ns) for 
two independent simulations of the apo protein and the protein complexed with product 5. 
The average RMSF of the two runs is also projected on representative structures ranging from 
blue (0 Å) to white to red (1.5 Å and higher); apo structure on the right, complex structure on 
the left. Structural elements that interact with the flexible loop in the closed structure show 













Fig. S8. Structural comparison of AbyU with the allene oxide cyclase pPAOC2. A, 
Superposition of AbyU (Blue) with pPAOC2 (Green). Both proteins are shown in cartoon 
representation. B, Comparison of the size, shape and location of the active sites of AbyU and 
pPAOC2. Both proteins are shown in space filling representation and are colored by 
electrostatic surface potential. The location of the active sites of AbyU and pPAOC2 are 
indicated by yellow asterisks. C, pPAOC2 catalyzed cyclization of the allene oxide 12,13-(S)-

























Fig. S9. Amino acid conservation in spirotetronate cyclases and structural implications. A, 
Comparative sequence alignment of AbyU with other spirotetronate cyclases. Included are 
QmnH-NTD (quartromicin, N-terminal domain of QmnH), QmnH-CTD (quartromicin, C-
terminal domain of QmnH), TcaU4 (tetrocarcin), KijCyc  (kijanimicin), LobD1  
(lobophorines), VstJ  (versipelostatin), AbyU  (abyssomicins), Tmn8 (tetronomycin), and 
ChlL (chlorothricin). Amino acids conserved in all the spirotetronate cyclases included in this 
analysis are highlighted in black boxes. Sequence alignments were performed using 
ClustalW2.32 The figure was generated using BOXSHADE 
(http://www.ch.embnet.org/software/BOX_form.html). B, Conserved amino acids identified 
in (A) mapped onto the crystal structure of AbyU. AbyU is shown in cartoon representation 
colored blue to red from N-terminus to C-terminus. Conserved amino acids are show in 
sphere representation and colored by atom. None of the conserved amino acids are located 






Fig. S10. Docking and QM/MM simulations of substrate and products in AbyU. Top half 
of panels A-D represent all 4 different docking poses of the AbyU product 5 (abyssomycin C 
without the ether-bridge, cyan carbons), together with the equivalent poses of the docked 
substrate (orange carbons) and the atropisomer product (magenta carbons). AbyU residues 
Phe41 and Trp124 are indicated for reference (green carbons). Docking ranks are indicated 
below. Bottom half of panels A-D indicate the results of QM/MM reaction simulations 
(starting from the docked product pose), if applicable. Free energies (as obtained from 
-S46- 	
	
QM/MM umbrella sampling simulations; see section S4.3 for details) are shown relative to the 
substrate minimum. Average distances of the forming carbon-carbon bonds (dCC1 = dC13-
C14; dCC2 = dC10-C15) from the sampling windows representing the substrate minimum 
and the transition state maximum are indicated. These values show that an asynchronous 
concerted mechanism is followed, with formation of the C13-C14 bond occurring first (and 
representing the reaction barrier). For the pose in panel B, no relevant reactive pathways 
could be obtained and for the pose in panel D only a single reactive pathway. The pose in 
panel A is favored by docking (consistent binding modes of substrate and products) and 
QM/MM simulation (reactive pathways with the lowest average free energy barrier and a clear 
substrate minimum). E, QM/MM free energy profiles (PMFs) of panel A in more detail. 
Average distances (+/− standard deviation) of the forming carbon-carbon bonds are indicated 

























Fig. S11. Transition states for the Diels-Alder reaction. Transition states were optimized in 
the gas-phase at the M06-2X/6-31G* level for the products of AbyU (see SI methods). A, 
Transition states of product 5 (abyssomycin C without the ether-bridge; green carbons, left) 
and its atropisomer (cyan carbons, right). The bond distances (indicated by blue dashed lines 
with distances in A) and single imaginary frequencies indicate that the reaction is 
asynchronous, with the bond formation between C13 and C14 occurring first. B, 
Approximate potential energy surface for the reaction, starting from the product, obtained by 
following the minimum energy path in B97D/6-31G* optimizations where either dC10-C15 
or dC13-C14 is increased (see SI methods). Single-point calculations using M06-2X/6-31G* 
(more accurate) or (SCC-)DFTB (more approximate), indicating that the overall shape 
between these levels of theory is similar, with (SCC-)DFTB underestimating the reaction 
barrier by ~7.3 kcal mol−1.  C & D, Depictions of the highest occupied (C) and lowest 
unoccupied (D) molecular orbitals (HOMO & LUMO) of the transition states (isovalue is 









 AbyU_DM AbyU 
Data collection   
Space group P212121 P1 
Cell dimensions   
   a, b, c (Å) 67.35, 68.27, 139.31 61.80, 73.59, 86.19 
   α, β, γ (°) 90, 90, 90 112.87, 90.04, 89.98 
Wavelength (Å) 0.91731 0.97298 
Resolution (Å) 29.78–1.77 (1.77-1.72) 79.41-2.36 (2.49-2.36) 
Rmerge (%) 0.106 (0.764) 0.12 (0.358) 
I/σI 27.8 (3.5) 6.4 (3.27) 
Completeness (%) 99.7 (95.9) 92.4 (73.7) 
Redundancy 24.1 (16.6) 3.3 (3.2) 
   
Refinement   
Resolution (Å) 29.78-1.77 79.41-2.36 
No. reflections 65871 52922 
Rwork/Rfree 20.1/22.1 20.9/25.0 
No. atoms 4203 8472 
   Protein 4061 8251 
   Ligand 45 150 
   Water 97 76 
B-factors   
   Protein 21.03 22.81 
   Ligand 39.72 26.16 
   Water 23.07 17.42 
Occupancies   
HEPES 1 1 
R.m.s. deviations   
   Bond lengths (Å) 0.008 0.007 
   Bond angles (°) 1.189 1.036 
   
 
Table S1. X-ray diffraction data collection, phasing and refinement statistics. Data in 
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